Skip to main content

Tactile Systems Technology Inc

TCMD
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001027838

In the last 90 days, Tactile Systems Technology Inc insiders filed 0 open-market purchases and 1 sale; 180 institutions reported holding it in 13F filings for Q2 2026, worth $652.2M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Tactile Systems Technology Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $323.2K in total
Insiders trading
1
Net value
−$323.2K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Tactile Systems Technology Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Tactile Systems Technology Inc
NameTitleLast reported holdingLast filingFilings, past year
Dodd Sheri LouiseChief Executive Officer232,907Aug 12, 20264
Birkemeyer Elaine M.CHIEF FINANCIAL OFFICER130,188May 13, 20264
Burke William WDirector55,041May 8, 20261
Volkart Carmen BDirector44,219May 8, 20261
Pearson AndreaDirector7,373May 8, 20262
Huggenberger RaymondDirector62,841May 8, 20261
Shafer David BrentDirector55,343May 8, 20261
Asbury Valerie L.Director55,343May 8, 20261
Washington Boyd VindellDirector41,768May 8, 20261
King Laura G.Director25,569May 8, 20261
Burns KristieSr. VP Mktg & Clinical Affairs82,581Feb 26, 20264
Reuvers Daniel L.Director68,162IndirectMar 13, 20250
Ferstler Sherri LeeSenior VP, Sales38,764Aug 14, 20240
Pauls EricSenior VP, Sales29,498May 10, 20230
Moen BrentChief Financial Officer48,760Mar 3, 20230
Jain DeeptiDirector15,448May 11, 20220
Roche Kevin HDirector66,228Oct 5, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 12, 2026 (view filing)4:22 PM ETAug 102 daysDodd Sheri LouiseChief Executive OfficerSSale−11.0K$29.44−$323.2K−4.5%232.9K after
May 13, 2026 (view filing)May 112 daysBirkemeyer Elaine M.CHIEF FINANCIAL OFFICERSSale−4.63K$24.49−$113.4K−3.4%130.2K after
Feb 26, 2026 (view filing)Feb 242 daysBirkemeyer Elaine M.CHIEF FINANCIAL OFFICERSSale−7.70K$28.94−$222.9K−5.4%134.8K after
Feb 26, 2026 (view filing)Feb 242 daysBurns KristieSr. VP Mktg & Clinical AffairsSSale−6.25K$28.94−$180.8K−7.0%82.6K after
Feb 26, 2026 (view filing)Feb 242 daysDodd Sheri LouiseChief Executive OfficerSSale−11.0K$28.94−$318.1K−4.3%243.9K after
Feb 24, 2026 (view filing)Feb 231 dayBirkemeyer Elaine M.CHIEF FINANCIAL OFFICERSSale−5.52K$28.29−$156.1K−3.7%142.5K after2 lots
Feb 24, 2026 (view filing)Feb 231 dayBurns KristieSr. VP Mktg & Clinical AffairsSSale−4.44K$28.29−$125.6K−4.8%88.8K after2 lots
Feb 24, 2026 (view filing)Feb 231 dayDodd Sheri LouiseChief Executive OfficerSSale−15.2K$28.29−$431.2K−5.6%254.9K after2 lots
Jan 6, 2026 (view filing)Jan 24 daysBurns KristieSr. VP Mktg & Clinical AffairsSSale−5.14K$28.85−$148.3K−6.6%72.4K after10b5-1
Aug 12, 2025 (view filing)Aug 84 daysDodd Sheri LouiseChief Executive OfficerSSale−7.76K$12.36−$95.9K−4.3%173.5K after
May 14, 2025 (view filing)May 122 daysBirkemeyer Elaine M.Chief Financial OfficerSSale−2.92K$9.94−$29.0K−2.9%99.1K after10b5-1
May 12, 2025 (view filing)May 84 daysDodd Sheri LouiseChief Executive OfficerSSale−3.15K$9.83−$31.0K−1.7%181.2K after
May 9, 2025 (view filing)May 81 dayBurke William WDirectorSSale−3.30K$9.67−$31.9K−6.4%48.5K after10b5-1
Feb 27, 2025 (view filing)Feb 252 daysBirkemeyer Elaine M.Chief Financial OfficerSSale−2.07K$14.51−$30.0K−2.0%102.0K after10b5-1
Feb 27, 2025 (view filing)Feb 252 daysBurns KristieSr. VP Mktg & Clinical AffairsSSale−6.47K$14.40−$93.1K−7.7%77.5K after
Feb 27, 2025 (view filing)Feb 252 daysReuvers Daniel L.DirectorSSale−28.3K$14.18−$401.8K−11.7%214.6K after10b5-1
Feb 24, 2025 (view filing)Feb 24Same dayReuvers Daniel L.DirectorSSale−10.9K$14.55−$159.1K−4.3%242.9K after10b5-1
Feb 24, 2025 (view filing)Feb 24Same dayBurns KristieSr. VP Mktg & Clinical AffairsSSale−4.83K$14.65−$70.8K−5.4%84.0K after
Feb 24, 2025 (view filing)Feb 24Same dayBirkemeyer Elaine M.Chief Financial OfficerSSale−3.78K$14.70−$55.5K−3.5%104.1K after10b5-1
Aug 14, 2024 (view filing)Aug 122 daysFerstler Sherri LeeSenior VP, SalesSSale−1.55K$13.07−$20.3K−3.8%38.8K after
May 20, 2024 (view filing)May 164 daysBirkemeyer Elaine M.Chief Financial OfficerSSale−3.04K$13.68−$41.6K−4.7%61.3K after
May 10, 2024 (view filing)May 82 daysBurke William WDirectorSSale−2.50K$14.06−$35.1K−9.0%25.3K after10b5-1
May 8, 2024 (view filing)May 62 daysBurns KristieSr. VP Mktg & Clinical AffairsSSale−815$14.37−$11.7K−1.3%62.6K after
Feb 29, 2024 (view filing)Feb 27-292 daysBurns KristieSr. VP Mktg & Clinical AffairsSSale−1.33K$15.52−$20.7K−2.1%63.4K after2 lots10b5-1
Feb 29, 2024 (view filing)Feb 27-292 daysReuvers Daniel L.President and CEOSSale−6.08K$15.52−$94.4K−2.5%238.0K after2 lots10b5-1
Feb 27, 2024 (view filing)Feb 23-264 daysReuvers Daniel L.President and CEOSSale−11.6K$15.37−$178.5K−4.5%244.1K after2 lots10b5-1
Feb 27, 2024 (view filing)Feb 23-264 daysBurns KristieSr. VP Mktg & Clinical AffairsSSale−4.26K$15.32−$65.3K−6.3%63.5K after2 lots10b5-1
Aug 9, 2023 (view filing)Aug 72 daysReuvers Daniel L.President and CEOSSale−1.06K$20.53−$21.8K−0.8%125.7K after
May 16, 2023 (view filing)May 124 daysBurke William WDirectorSSale−4.40K$21.86−$96.2K−13.7%27.8K after10b5-1
May 10, 2023 (view filing)May 82 daysBurns KristieSr. VP Mktg & Clinical AffairsSSale−786$18.65−$14.7K−2.1%36.6K after10b5-1
May 10, 2023 (view filing)May 82 daysPauls EricSenior VP, SalesSSale−550$18.55−$10.2K−1.8%29.5K after10b5-1
Mar 3, 2023 (view filing)Mar 12 daysMoen BrentChief Financial OfficerSSale−1.39K$14.10−$19.6K−2.8%48.8K after
Feb 28, 2023 (view filing)Feb 27-281 dayReuvers Daniel L.President and CEOSSale−7.09K$15.20−$107.7K−5.3%126.7K after2 lots
Feb 28, 2023 (view filing)Feb 27-281 dayMoen BrentChief Financial OfficerSSale−4.05K$15.31−$62.0K−7.5%50.2K after2 lots
Feb 28, 2023 (view filing)Feb 27-281 dayBurns KristieSr. VP Mktg & Clinical AffairsSSale−2.30K$15.34−$35.2K−5.8%37.3K after2 lots
Feb 28, 2023 (view filing)Feb 27-281 dayPauls EricSenior VP, SalesSSale−1.47K$15.29−$22.5K−4.7%30.0K after2 lots
Aug 10, 2022 (view filing)Aug 82 daysReuvers Daniel L.President and CEOSSale−1.02K$9.18−$9.36K−1.3%74.7K after
Aug 8, 2022 (view filing)Aug 44 daysBurke William WDirectorPPurchase+4.90K$9.15+$44.8K+25.1%24.4K after
May 23, 2022 (view filing)May 194 daysBurke William WDirectorSSale−1.10K$10.12−$11.1K−5.3%19.5K after
May 10, 2022 (view filing)May 64 daysBurns KristieSr. VP Mktg & Clinical AffairsSSale−999$13.04−$13.0K−4.4%22.0K after
May 10, 2022 (view filing)May 64 daysPauls EricSenior VP, SalesSSale−600$13.03−$7.82K−3.2%18.3K after
Mar 9, 2022 (view filing)Mar 72 daysMoen BrentChief Financial OfficerSSale−176$20.64−$3.63K−0.3%51.9K after
Mar 3, 2022 (view filing)Mar 12 daysMoen BrentChief Financial OfficerSSale−1.63K$20.33−$33.2K−3.0%52.1K after
Feb 28, 2022 (view filing)Feb 28Same dayReuvers Daniel L.President and CEOSSale−877$19.78−$17.3K−1.1%75.7K after
Feb 28, 2022 (view filing)Feb 28Same dayMoen BrentChief Financial OfficerSSale−624$19.85−$12.4K−1.1%53.7K after
Aug 9, 2021 (view filing)Aug 63 daysReuvers Daniel L.President and CEOSSale−1.06K$43.11−$45.8K−4.5%22.7K after
Jul 7, 2021 (view filing)Jul 7Same dayReuvers Daniel L.President and CEOSSale−2.96K$49.75−$147.3K−11.1%23.7K after